The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment)
Given the cost of hospital-acquired and healthcare-associated infections (HAIs), demand has increased for solutions that can help the healthcare industry reduce infections and the costs associated with them. The U.S. Centers for Disease Control and Prevention (CDC) estimates that around 1 in 20 or 5% of hospitalized patients will contract an HAI. Worldwide, the rate of nosocomial infections is between 3.5% and 12% of admissions in developed regions. This has created a market opportunity for companies that can test for, treat and help prevent these infections. This opportunity is detailed in Kalorama Information's report, The Market for Hospital-Acquired Infection Control (Sterilization, Cleaning, Testing, Treatment)
This report focuses on preventing, testing and treating infections in the healthcare environment. The major consideration is given to bacterial nosocomial infections because a) they are the most frequent type of infections spread in the health care delivery setting, and b) the practical aspects of diagnosis and therapy are more meaningful based on a combination of medical and financial considerations.
The report will provide a market analysis in the areas of Prevention, Testing and Treatment.
Market analysis in this report considers primarily the epidemiological considerations and the size patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis.
Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital and primary care environment in order to construct a picture of the infection prevention, testing and treatment needs.
In looking at infections in the health environment, we consider the diagnostic and therapeutic technologies that are currently available and attempt to project trends for preventing, detecting and treating these infections. To some extent, we are limited by the activity of the industries associated with the activities mentioned above for these infections. For the most part, these activities are limited and the advanced technologies seen in other areas of medical application are not necessarily present in terms of microbiology.
The majority of competitive participation for Hospital-Acquired Infection control and is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. Companies in this report include:
This report focuses on preventing, testing and treating infections in the healthcare environment. The major consideration is given to bacterial nosocomial infections because a) they are the most frequent type of infections spread in the health care delivery setting, and b) the practical aspects of diagnosis and therapy are more meaningful based on a combination of medical and financial considerations.
The report will provide a market analysis in the areas of Prevention, Testing and Treatment.
Market analysis in this report considers primarily the epidemiological considerations and the size patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis.
Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital and primary care environment in order to construct a picture of the infection prevention, testing and treatment needs.
In looking at infections in the health environment, we consider the diagnostic and therapeutic technologies that are currently available and attempt to project trends for preventing, detecting and treating these infections. To some extent, we are limited by the activity of the industries associated with the activities mentioned above for these infections. For the most part, these activities are limited and the advanced technologies seen in other areas of medical application are not necessarily present in terms of microbiology.
The majority of competitive participation for Hospital-Acquired Infection control and is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. Companies in this report include:
- Advanced Sterilization Products
- Becton Dickinson
- Belimed AG
- bioMerieux
- Cantel
- Cepheid
- Kimberly-Clark
- Merck & Co.
- Nordion
- Pfizer
- Roche
- Steris
- TSO3
CHAPTER ONE: EXECUTIVE SUMMARY
Overview
The Nosocomial Infection
Scope and Methodology
Total Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors
CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
Overview
Introduction to Pathogens
Classification of Antibacterial Organisms
Patient Risk Factors
General Infection Statistics
Populations at Risk for Infection
Demographics of the World
Life Expectancy
Nosocomial Infection Statistics
Common Hospital (nosocomial) Infections
Description of Infections
Infection Risk Assessments by Hospital Department
Burn Units
Intensive Care Units
Emergency Departments
Hospital Length of Stay
Extended Stay Environments
International Trends in Nursing Facilities
Economic Trends
Comparison Between Healthcare Spending and Real Health Outcomes
U.S. Government's National Plan to Prevent Healthcare Associated Infections (HAIs)
Steering Committee
The American Recovery and Reinvestment Act of 2009
Affordable Care Act (ACA) Funding
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Funding
U.S. Statewide Standardized Infection Ratio
Reduction in Hospital Acquired Infections
Reduction in Infections in Israel
Burden of Hospital Acquired Infections
Hospital-Acquired Infection Surveillance Process
Case Studies
Arizona Prevention Study
Connecticut Funding for HAI Prevention and Reporting
Pennsylvania Study of HAI Admissions and Readmissions
Infections and Drug Resistance
Easing Approvals of Antibiotics
Causes of Drug Resistance
Antibiotic Abuse
Antibiotic Use in Agriculture
Drug Resistance in Select Populations
Children
The Elderly
Compromised Individuals
Measures for Reducing Resistance
Testing for the Selection of Anti-bacterial Therapy
Monitoring Therapy
Screening Hospitalized patients
Pharmaceutical Manufacturer and Marketer Trends
Trends in Partnerships and Alliances
Developers Trends
CHAPTER THREE: INFECTION PREVENTION
Overview
Methods of Transmission
Airborne
Contact
Droplet
Vehicle
High-Risk Facilities or Departments
Technology Overview
Potential Use of Copper for Reducing Infections
Wide Area Disinfection Methods
Software for Infection Detection and Control
Antiseptic-Coated Catheters
Sterilization vs. Disinfection
Sterilization
Disinfection
Equipment and Solutions
Heat/Steam Sterilization
Developments
Chemical Sterilization
Sterilants
Developments
Radiation Sterilization
Developments
Market Overview
Hospital-Acquired Infection Prevention Market by Geographical Region
Competitive Analysis
CHAPTER FOUR: INFECTION TESTING
Overview
Drug-Resistance/Susceptibility Testing
Genotypic Methods
DNA Sequencing
Solid-phase Hybridization Techniques
Microarrays
Real-time Polymerase Chain Reaction Techniques
Phenotypic Methods
Phage-based Assays
Colorimetric Methods
The Nitrate Reductase Assay
Specific Serious Hospital-Acquired Infection Testing
Acinetobacter Baumannii
Clostridium Difficile
Developments
Hospital-Acquired Pneumonia
Pseudomonas Aeruginosa
Staphylococcus Aureus
Methicillin-resistant Staphylococcus Aureus (MRSA)
Vancomycin-Intermediate/Resistant Staphylococcus Aureus (VISA/VRSA)
Developments
Tuberculosis
Developments
Urinary Tract Infections
Vancomycin-resistant Enterococcus
Developments
Ventilator-Associated Pneumonia
New Developments
Market Overview
Total Market Size and Forecast
Hospital-Acquired Infection Testing Market by Geographical Region
Competitive Analysis
CHAPTER FIVE: INFECTION TREATMENT
Overview
Principles of Anti-bacterial Therapy
Infecting Organism
Antibiotic Sensitivity Testing
Site of Infection
Host Defenses and Organ Function
Antibiotic Pharmacokinetics
Monitoring Therapy
Classifications of Antibacterial Products
Carbapenems
Cephalosporins
Macrolides
Penicillins
Quinolones
Sulfonamides
Tetracyclines
Treatment Guidelines
Clostridium Difficile
Gastroenteritis
Hospital-Acquired Pneumonia
Ventilator-associated Pneumonia
Pseudomonas Aeruginosa
Staphylococcus Aureus
Stenotrophomonas maltophilia
Tuberculosis
Urinary Tract Infections
Leading Products
New Developments
Total Market Size and Forecast
Hospital-Acquired Infection Treatment Market by Geographical Region
Competitive Analysis
CHAPTER SIX: MARKET OPPORTUNITIES FOR HOSPITAL-ACQUIRED INFECTION CONTROL
Market Considerations
Market Overview
Hospital-Acquired Infection Control Market by Geographical Region
CHAPTER SEVEN: COMPANY PROFILES
Introduction
Advanced Sterilization Products
Company Performance
Becton, Dickinson
Company Performance
Belimed
Company Performance
bioMerieux
Company Performance
Cantel
Company Performance
Cepheid
Company Performance
Getinge Group
Company Performance
Kimberly-Clark
Company Performance
Merck & Co
Company Performance
Nordion
Company Performance
Pfizer
Company Performance
Roche
Company Performance
Sakura Seiki
Steris
Company Performance
Tso3
Company Performance
LIST OF MAJOR PROVIDERS
Overview
The Nosocomial Infection
Scope and Methodology
Total Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors
CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
Overview
Introduction to Pathogens
Classification of Antibacterial Organisms
Patient Risk Factors
General Infection Statistics
Populations at Risk for Infection
Demographics of the World
Life Expectancy
Nosocomial Infection Statistics
Common Hospital (nosocomial) Infections
Description of Infections
Infection Risk Assessments by Hospital Department
Burn Units
Intensive Care Units
Emergency Departments
Hospital Length of Stay
Extended Stay Environments
International Trends in Nursing Facilities
Economic Trends
Comparison Between Healthcare Spending and Real Health Outcomes
U.S. Government's National Plan to Prevent Healthcare Associated Infections (HAIs)
Steering Committee
The American Recovery and Reinvestment Act of 2009
Affordable Care Act (ACA) Funding
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Funding
U.S. Statewide Standardized Infection Ratio
Reduction in Hospital Acquired Infections
Reduction in Infections in Israel
Burden of Hospital Acquired Infections
Hospital-Acquired Infection Surveillance Process
Case Studies
Arizona Prevention Study
Connecticut Funding for HAI Prevention and Reporting
Pennsylvania Study of HAI Admissions and Readmissions
Infections and Drug Resistance
Easing Approvals of Antibiotics
Causes of Drug Resistance
Antibiotic Abuse
Antibiotic Use in Agriculture
Drug Resistance in Select Populations
Children
The Elderly
Compromised Individuals
Measures for Reducing Resistance
Testing for the Selection of Anti-bacterial Therapy
Monitoring Therapy
Screening Hospitalized patients
Pharmaceutical Manufacturer and Marketer Trends
Trends in Partnerships and Alliances
Developers Trends
CHAPTER THREE: INFECTION PREVENTION
Overview
Methods of Transmission
Airborne
Contact
Droplet
Vehicle
High-Risk Facilities or Departments
Technology Overview
Potential Use of Copper for Reducing Infections
Wide Area Disinfection Methods
Software for Infection Detection and Control
Antiseptic-Coated Catheters
Sterilization vs. Disinfection
Sterilization
Disinfection
Equipment and Solutions
Heat/Steam Sterilization
Developments
Chemical Sterilization
Sterilants
Developments
Radiation Sterilization
Developments
Market Overview
Hospital-Acquired Infection Prevention Market by Geographical Region
Competitive Analysis
CHAPTER FOUR: INFECTION TESTING
Overview
Drug-Resistance/Susceptibility Testing
Genotypic Methods
DNA Sequencing
Solid-phase Hybridization Techniques
Microarrays
Real-time Polymerase Chain Reaction Techniques
Phenotypic Methods
Phage-based Assays
Colorimetric Methods
The Nitrate Reductase Assay
Specific Serious Hospital-Acquired Infection Testing
Acinetobacter Baumannii
Clostridium Difficile
Developments
Hospital-Acquired Pneumonia
Pseudomonas Aeruginosa
Staphylococcus Aureus
Methicillin-resistant Staphylococcus Aureus (MRSA)
Vancomycin-Intermediate/Resistant Staphylococcus Aureus (VISA/VRSA)
Developments
Tuberculosis
Developments
Urinary Tract Infections
Vancomycin-resistant Enterococcus
Developments
Ventilator-Associated Pneumonia
New Developments
Market Overview
Total Market Size and Forecast
Hospital-Acquired Infection Testing Market by Geographical Region
Competitive Analysis
CHAPTER FIVE: INFECTION TREATMENT
Overview
Principles of Anti-bacterial Therapy
Infecting Organism
Antibiotic Sensitivity Testing
Site of Infection
Host Defenses and Organ Function
Antibiotic Pharmacokinetics
Monitoring Therapy
Classifications of Antibacterial Products
Carbapenems
Cephalosporins
Macrolides
Penicillins
Quinolones
Sulfonamides
Tetracyclines
Treatment Guidelines
Clostridium Difficile
Gastroenteritis
Hospital-Acquired Pneumonia
Ventilator-associated Pneumonia
Pseudomonas Aeruginosa
Staphylococcus Aureus
Stenotrophomonas maltophilia
Tuberculosis
Urinary Tract Infections
Leading Products
New Developments
Total Market Size and Forecast
Hospital-Acquired Infection Treatment Market by Geographical Region
Competitive Analysis
CHAPTER SIX: MARKET OPPORTUNITIES FOR HOSPITAL-ACQUIRED INFECTION CONTROL
Market Considerations
Market Overview
Hospital-Acquired Infection Control Market by Geographical Region
CHAPTER SEVEN: COMPANY PROFILES
Introduction
Advanced Sterilization Products
Company Performance
Becton, Dickinson
Company Performance
Belimed
Company Performance
bioMerieux
Company Performance
Cantel
Company Performance
Cepheid
Company Performance
Getinge Group
Company Performance
Kimberly-Clark
Company Performance
Merck & Co
Company Performance
Nordion
Company Performance
Pfizer
Company Performance
Roche
Company Performance
Sakura Seiki
Steris
Company Performance
Tso3
Company Performance
LIST OF MAJOR PROVIDERS
Gastroenteritis
Gastroenteritis is a condition that causes irritation and inflammation of the stomach and intestines of the gastrointestinal tract. Diarrhea, crampy abdominal pain, nausea, and vomiting are the most common symptoms. Viral infection is the most common cause of gastroenteritis but bacteria, parasites, and food-borne illness (such as shellfish) can be the offending agent. Nosocomial gastroenteritis can be caused by bacteria or viruses (most frequently, viruses).
Bacterial causes of gastro enteritis include infection with:
- Staphylococcus aureus
- E. coli
- Salmonella
- Shigella
- Campylobacter
- C. difficile
Classifications of Antibacterial Products
Several classifications of antibacterials are available for treating infections:
- Carbapenems
- Cephalosporins
- Macrolides
- Penicillins
- Quinolones
- Sulfonamides
- Tetracyclines
